Asset
Canvuparatide
MBX Biosciences Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06496217 | phase1 | completed | 2024-06-13 | 2025-09-04 | MBX Biosciences | Safety and Pharmacokinetics Study of MBX 2109 in Adult Subjects With Normal and Impaired Renal Function |
| NCT06465108 | phase2 | completed | 2024-08-08 | 2025-05-23 | MBX Biosciences | Safety, Pharmacokinetics and Efficacy of MBX 2109 in Patients With Hypoparathyroidism |
| NCT05158335 | phase1 | completed | 2021-11-10 | 2023-06-20 | MBX Biosciences | Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of MBX 2109 in Healthy Adult Subjects |
FDA applications (0)
This company has no applications containing this asset.